These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1316253)

  • 1. Use of succimer.
    Marcus SM; Ruck B
    Clin Pharm; 1992 May; 11(5):387-8; author reply 388-9. PubMed ID: 1316253
    [No Abstract]   [Full Text] [Related]  

  • 2. Succimer: the first approved oral lead chelator.
    Jorgensen FM
    Am Fam Physician; 1993 Dec; 48(8):1496-502. PubMed ID: 8249780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1991 Apr; 265(14):1802. PubMed ID: 1848642
    [No Abstract]   [Full Text] [Related]  

  • 4. Succimer--an oral drug for lead poisoning.
    Med Lett Drugs Ther; 1991 Aug; 33(850):78. PubMed ID: 1649375
    [No Abstract]   [Full Text] [Related]  

  • 5. Succimer: controversial issues involving the release of a new product.
    Banner W
    Clin Pharm; 1991 Dec; 10(12):942. PubMed ID: 1663440
    [No Abstract]   [Full Text] [Related]  

  • 6. Succimer in symptomatic lead poisoning.
    Kalra V; Dua T; Kumar V; Kaul B
    Indian Pediatr; 2002 Jun; 39(6):580-5. PubMed ID: 12084955
    [No Abstract]   [Full Text] [Related]  

  • 7. Succimer, an oral lead chelator.
    Mann KV; Travers JD
    Clin Pharm; 1991 Dec; 10(12):914-22. PubMed ID: 1663439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1989 annual survey--133 orphan drug products.
    Hosp Pharm; 1990 Apr; 25(4):367-71, 375-86. PubMed ID: 10104391
    [No Abstract]   [Full Text] [Related]  

  • 9. Orphan drug development for the treatment of rare chronic diseases.
    Moore ES
    Tex Hosp; 1988 Jul; 44(2):20-1. PubMed ID: 10288218
    [No Abstract]   [Full Text] [Related]  

  • 10. Orphan drug development in the United States.
    Groft SC
    CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Problems associated with developing orphan drugs into available therapy.
    Van Woert MH
    Prog Clin Biol Res; 1985; 197():171-3. PubMed ID: 4070291
    [No Abstract]   [Full Text] [Related]  

  • 12. View from the Nation's Capital.
    Romansky MA
    J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA's interferon-beta decision reignites orphan debate.
    Marshall A
    Nat Biotechnol; 1999 Apr; 17(4):324-5. PubMed ID: 10207871
    [No Abstract]   [Full Text] [Related]  

  • 14. When drugs are in short supply.
    Zurlinden J
    Nurs Spectr (Wash D C); 1999 Feb; 9(4):15-6. PubMed ID: 10542818
    [No Abstract]   [Full Text] [Related]  

  • 15. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
    Koivuniemi PJ
    Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
    [No Abstract]   [Full Text] [Related]  

  • 16. The Orphan Drug Act: an engine of innovation? At what cost?
    Rohde DD
    Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
    [No Abstract]   [Full Text] [Related]  

  • 17. Orphan Drug Act on congressional agenda.
    von Oehsen WH
    Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [2,3-dimercaptosuccinic acid: a new chelating agent, safe and efficacious, for lead poisoning].
    Nogué S; Sanz-Gallén P; Munné P; To-Figueras J
    Med Clin (Barc); 1993 Oct; 101(12):478-9. PubMed ID: 8231377
    [No Abstract]   [Full Text] [Related]  

  • 19. View from the Nation's Capital.
    Romansky MA
    J Clin Psychopharmacol; 1983 Feb; 3(1):47-8. PubMed ID: 6680403
    [No Abstract]   [Full Text] [Related]  

  • 20. [Ambulatory treatment for lead poisoning].
    Otermin Maia I; Belzunce Elizalde M
    An Med Interna; 2002 Aug; 19(8):440-1. PubMed ID: 12244800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.